Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      Service de Médecine Nucléaire Saint-Louis; Hopital Saint-Louis AP-HP (AP-HP); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Université Paris Cité (UPCité); Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité); Service de Dermatologie AP-HP Hôpital Saint-Louis; Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal Paris; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord
    • بيانات النشر:
      HAL CCSD
      MDPI
    • الموضوع:
      2022
    • Collection:
      Université Paris 13: HAL
    • نبذة مختصرة :
      International audience ; Background: Immune checkpoint inhibitors (ICI) are currently the first-line treatment for patients with metastatic melanoma. We investigated the value of positron emission tomography (PET) response criteria to assess the therapeutic response to first-line ICI in this clinical context and explore the potential contribution of total tumor metabolic volume (TMTV) analysis. Methods: We conducted a retrospective study in patients treated with first-line ICI for advanced or metastatic melanoma, with 18F-FDG PET/CT performed at baseline and 3 months after starting treatment. Patients’ metabolic response was classified according to PERCIST5 and imPERCIST 5 criteria. TMTV was recorded for each examination. Results: Twenty-nine patients were included. The median overall survival (OS) was 51.2 months (IQR 13.6—not reached), and the OS rate at 2 years was 58.6%. Patients classified as responders (complete and partial response) had a 90.9% 2-year OS rate versus 38.9% for non-responders (stable disease and progressive disease) (p = 0.03), for PERCIST5 and imPERCIST 5 criteria. The median change in metabolic volume was 9.8% (IQR −59–+140%). No significant correlation between OS and changes in TMTV was found. Conclusion: The evaluation of response to immunotherapy using metabolic imaging with PERCIST5 and imPERCIST5 was significantly associated with OS in patients with advanced or metastatic melanoma.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/35804963; inserm-03924569; https://inserm.hal.science/inserm-03924569; https://inserm.hal.science/inserm-03924569/document; https://inserm.hal.science/inserm-03924569/file/cancers-14-03190.pdf; PUBMED: 35804963; PUBMEDCENTRAL: PMC9264956
    • الرقم المعرف:
      10.3390/cancers14133190
    • الدخول الالكتروني :
      https://inserm.hal.science/inserm-03924569
      https://inserm.hal.science/inserm-03924569/document
      https://inserm.hal.science/inserm-03924569/file/cancers-14-03190.pdf
      https://doi.org/10.3390/cancers14133190
    • Rights:
      info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.3E07B666